Osteosarcoma: Future Strategies for Improving Survival

Researchers review findings in chemotherapy resistance and cancer “stem cells”

Terry Stanton

Osteosarcoma is problematic. Although it is the most common primary bone sarcoma, it has an incidence of only about 1,000 cases per year in the United States. Its relative rarity constricts the scope of clinical trials that can be conducted and directs researchers to other strategies in their quests to discover effective therapies.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!